Literature DB >> 22622515

Management of atrial fibrillation in the acute setting.

James Chenoweth1, Deborah B Diercks.   

Abstract

PURPOSE OF REVIEW: The review aims to describe the scope of the problem and potential therapeutic intervention for the management and risk stratification of patients with atrial fibrillation in the emergency department and acute care setting. RECENT
FINDINGS: Atrial fibrillation is the most common arrhythmia prompting admission to the hospital. Management strategies include determining the trigger of the arrhythmia, rate control, and potential cardioversion. In the acute care setting the treatment is often dependent on the timing of the onset of arrhythmia. In those patients presenting with symptoms of less than 48 h of duration management may consist of rate control, pharmacologic, or electrical cardioversion. Recent studies suggest no difference in long-term outcomes with rate and rhythm control. In patients with symptoms greater that 48 h rate control is the initial option with potential for cardioversion as an outpatient. There are recent advances in ablation that provide additional options to patients with paroxysmal atrial fibrillation. An essential component of the treatment strategy for these patients is risk stratification for stroke and the initiation of long-term anticoagulation in appropriate patients.
SUMMARY: Management of atrial fibrillation is guided by underlying causes of the atrial fibrillation and duration of symptoms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622515     DOI: 10.1097/MCC.0b013e328354dc30

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  1 in total

1.  The Novel CHA2DS2-VASC-FSH Score is Predictive of Severe Coronary Artery Disease on Coronary Angiography in Patients with Atrial Fibrillation and Unstable Symptoms.

Authors:  Orcun Ciftci; Kerem Can Yilmaz; Emir Karacaglar; Mustafa Yilmaz; Bulent Ozin; Ibrahim Haldun Muderrisoglu
Journal:  Eurasian J Med       Date:  2019-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.